Carolyn Keating, PhD
About Carolyn Keating, PhD
Carolyn Keating, PhD, serves as the Associate Scientific Director at PRECISIONscientia, where she has worked since 2022. She has played a key role in launching the first FDA-approved treatment for a genetic immune disease and manages a team of medical writers while providing strategic recommendations for future initiatives.
Work at PRECISIONscientia
Carolyn Keating serves as the Associate Scientific Director at PRECISIONscientia, a position she has held since 2022. In this role, she provides strategic recommendations for future initiatives and content. She is responsible for producing a variety of deliverables aimed at healthcare professionals, patients, and internal clients. These deliverables include advisory boards, congress materials, and publications. Additionally, she manages two direct reports who work as medical writers.
Education and Expertise
Carolyn Keating holds a PhD, which underpins her expertise in the medical field. Her work primarily focuses on the rare disease space, where she integrates knowledge from both medical and marketing sectors. Her academic background and professional experience contribute to her ability to navigate complex scientific and regulatory landscapes.
Background
Carolyn Keating has a notable background in the healthcare industry, particularly in the area of rare diseases. She played a significant role in launching the first FDA-approved treatment for a genetic immune disease, highlighting her involvement in critical advancements in medical treatment. Her experience spans both scientific and marketing domains, allowing her to effectively bridge the gap between these sectors.
Achievements
Among Carolyn Keating's key achievements is her contribution to the launch of the first FDA-approved treatment for a genetic immune disease. This milestone reflects her capability to impact the field of rare diseases significantly. Her ongoing work at PRECISIONscientia further emphasizes her commitment to advancing healthcare solutions and improving patient outcomes.